Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Redcare Pharmacy Aktie 34117753 / NL0012044747

06.10.2025 06:45:03

EQS-News: Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx. 

EQS-News: Redcare Pharmacy N.V. / Key word(s): Development of Sales/Preliminary Results
Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx. 

06.10.2025 / 06:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Redcare Pharmacy confirms full-year guidance following sustained positive Q3 sales performance in both Rx and non-Rx. 

  • Total sales up 25% to EUR 719M in Q3.
  • YTD total sales up 27% or EUR 450M to EUR 2.15bn.
  • Non-Rx sales up 17% to EUR 448M in Q3; YTD 18% to EUR 1.4bn.
  • Rx sales in Germany up 82% to EUR 126M in Q3, YTD 122% and EUR 348M.
  • Number of active customers up 0.2M, reaching 13.7M. NPS up, to well over 70.
  • Company reaffirms all elements of full-year guidance.

Sevenum, the Netherlands, 6 October 2025. Redcare Pharmacy N.V. today announced its preliminary and unaudited third quarter sales numbers. The Group’s total sales increased 25.2% to EUR 719 million (Q3 2024: EUR 575 million). Both reporting segments, DACH and International, achieved over 25% fully organic sales growth in Q3, 25.2% and 25.4% respectively. Non-Rx sales increased 16.7% to EUR 448 million (Q3 2024: EUR 383 million) and total Rx sales 42.3% to EUR 272 million (Q3 2024: EUR 191 million). In Germany, Rx sales totaled EUR 126 million, an increase of 82.1% year over year (Q3 2024: EUR 69 million). At the end of the quarter, Redcare Pharmacy recorded 13.7 million active customers and a significant improvement in the net promoter score (NPS) to well over 70, vs. 64 in H1 of the current year.

Redcare Pharmacy’s CEO Olaf Heinrich comments: “We are delivering strong Q3 momentum, especially in German Rx where we grew double-digits quarter over quarter, and confirm full-year guidance. Growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%.”

Strong momentum in Rx.

Entering Q4 with accelerated Rx growth in Germany and the customary seasonal uplift in order volumes in the final quarter of the year, the Group remains on track to achieve at least EUR 500 million Rx sales for the year. Accordingly, Redcare Pharmacy reaffirms its full-year guidance for Rx, as well as for all other elements.

Sales by reporting segments.

Sales in the DACH segment (Germany, Austria and Switzerland) increased 25.2% in Q3 to EUR 587 million (Q3 2024: EUR 469 million). Non-Rx sales grew 13.4% to EUR 315 million (Q3 2024: EUR 278 million), while prescription medication sales (Rx) grew 42.3% to EUR 272 million (Q3 2024: EUR 191 million). Year to date, total sales were EUR 1.74 billion, up 26.7% versus last year.

In the International segment (Belgium, Italy, France and the Netherlands) sales also maintained a fast pace of growth, increasing 25.4% to EUR 132 million (Q3 2024: EUR 105 million). Year to date, sales were EUR 402 million, up 25.9% versus last year.


Management confirms that financial steering remains fully stable throughout the current transition period, with continuity ensured until the appointment of a new CFO.

All published figures are preliminary and unaudited. Redcare Pharmacy N.V. will release the full interim report for the third quarter of 2025 on 29 October 2025.

 

Investor Relations Contact:

Monica Ambrosi (Associate Director, Investor Relations)

investors@redcare-pharmacy.com

 

Press Contact:

Sven Schirmer (Director, Corporate Communications)

press@redcare-pharmacy.com

 

 

About Redcare Pharmacy.

Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven.

As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products (BPC) as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands.

Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.



06.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Redcare Pharmacy N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: investors@redcare-pharmacy.com
Internet: www.redcare-pharmacy.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y072
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2208236

 
End of News EQS News Service

2208236  06.10.2025 CET/CEST

Analysen zu Redcare Pharmacy (ex Shop Apotheke)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
09:17 Redcare Pharmacy Buy Baader Bank
08:32 Redcare Pharmacy Sell UBS AG
07:43 Redcare Pharmacy Buy Jefferies & Company Inc.
30.09.25 Redcare Pharmacy Buy Deutsche Bank AG
18.09.25 Redcare Pharmacy Buy Jefferies & Company Inc.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Krypto-ETPs im Fokus: Regulierung, Verwahrung & Produktentwicklung | BX Swiss TV

David Kunz spricht mit Vera Claas, Geschäftsführerin von nxtAssets über die Zukunft von Krypto-ETPs. Im Fokus stehen physisch hinterlegte Bitcoin- und Ethereum-Produkte, regulatorische Rahmenbedingungen und die strategische Ausrichtung des Unternehmens. Auch geplante Produktentwicklungen und Zielgruppen kommen zur Sprache.

Themen im Video:
🔹 Die Idee hinter nxtAssets
🔹 warum physische Besicherung und Verwahrung ein echter Gamechanger für Bitcoin- und Ethereum-ETPs sind
🔹 regulatorische Vorteile im Vergleich zu internationalen Anbietern
🔹 institutionelle Investoren, Due Diligence und Vertrauen
🔹 Zukunftspläne: Baskets, neue ETPs & digitale Assets
🔹 Defi & Ethereum – das persönliche Lieblingsprojekt von Vera Claas

Krypto-ETPs im Fokus: Regulierung, Verwahrung & Produktentwicklung | BX Swiss TV

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’056.67 19.45 UBSIIU
Short 13’318.17 13.78 3OUBSU
Short 13’828.58 8.83 UFLBSU
SMI-Kurs: 12’551.36 06.10.2025 17:30:44
Long 12’011.46 19.30 SW5B0U
Long 11’710.13 13.20 SWFBJU
Long 11’248.74 8.96 B1PS3U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}